P/E ratio for Nymox Pharmaceutical (NYMX)
P/E ratio as of October 2023 (TTM): -3.33
According to Nymox Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.33333. At the end of 2021 the company had a P/E ratio of -6.33.
P/E ratio history for Nymox Pharmaceutical from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -6.33 | -59.95% |
| 2020 | -15.8 | 33.53% |
| 2019 | -11.8 | 35.77% |
| 2018 | -8.72 | -31.28% |
| 2017 | -12.7 | 33.1% |
| 2016 | -9.54 | 36.63% |
| 2015 | -6.98 | 145.21% |
| 2014 | -2.85 | -93.44% |
| 2013 | -43.4 | 41.65% |
| 2012 | -30.6 | 11.71% |
| 2011 | -27.4 | -9.49% |
| 2010 | -30.3 | 13.61% |
| 2009 | -26.6 | 27.29% |
| 2008 | -20.9 | -34.58% |
| 2007 | -32.0 | 69.41% |
| 2006 | -18.9 | 25.93% |
| 2005 | -15.0 | -20.77% |
| 2004 | -18.9 | 5.51% |
| 2003 | -17.9 | -22.21% |
| 2002 | -23.1 | -17.2% |
| 2001 | -27.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 31.2 | -1,036.16% | 🇺🇸 USA |
 Pfizer PFE | 8.88 | -366.54% | 🇺🇸 USA |
 Abbott Laboratories ABT | 29.1 | -971.67% | 🇺🇸 USA |
 Eli Lilly LLY | 75.8 | -2,374.70% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 17.3 | -620.42% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.